Vandetanib May Not Be Effective for Advanced Biliary Tract Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, researchers have found that vandetanib did not improve progression-free survival in patients with advanced biliary tract cancer.
For the phase 2 multi center study, researchers sought to investigate the safety and efficacy of vandetanib alone compared with vandetanib with gemcitabine or gemcitabine plus placebo in patients with advanced biliary tract cancer.
Researchers enrolled 173 patients and randomly assigned them 1:1:1 to receive either vandetanib 300mg orally daily alone, vandetanib 100mg orally daily plus gemcitabine 1,000mg/m2 IV on days 1 and 8 of each 21-day cycle, or gemcitabine 1,000mg/m2 IV on days 1 and 8 of each 21-day cycle plus placebo.
Results showed that the median progression-free survival was 105 days (95% CI: 72 - 155) for vandetanib monotherapy, 114 days (95% CI: 91 - 193) for vandetanib plus gemcitabine, and 148 days (95% CI: 71 - 225) for gemcitabine plus placebo (P = 0.18).
In addition, the vandetanib plus gemcitabine combination provided a slightly higher objective response rate over the other interventions. In regard to safety, the incidence of adverse effects was similar across all three treatment arms.
Vandetanib did not improve progression-free survival in patients with advanced biliary tract cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance
- Exercise May Mitigate Doxorubicin-related Cardiotoxicity
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia
- Minimal Residual Disease and Patient Genotype May Inform Relapse Risk Algorithms in ALL